AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$TELO

Telomir Pharmaceuticals, Inc.

Price · $TELOvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $TELO in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $TELO in the last 30 days.

Top stories · $TELOMore →
MAY 20·ACCESS NewswireHigh

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing that Telomir-Zn significantly improved survival and multiple endpoints in a Wilson's disease model. The study, published in Advances in Redox Research, demonstrated that Telomir-Zn reduced oxidative stress, hepatic copper burden, and tissue degeneration, while improving liver biomarkers and locomotor function. These findings support Telomir-Zn's biological activity in Wilson's disease and its broader mechanistic relevance across other diseases involving oxidative stress and dysregulated metal homeostasis, including Triple-Negative Breast Cancer.

APR 24·TipRanks

Telomir Pharmaceuticals Completes TELI Acquisition, Expands Telomir-1 Rights

Telomir Pharmaceuticals, Inc. (TELO) has finalized its acquisition of TELI Pharmaceuticals, Inc. on April 22, 2026, issuing 34,389,710 restricted common shares to former TELI shareholders. This acquisition, which included a $1 million contribution from Bayshore Trust with an option for an additional $4 million, consolidates all global rights to Telomir-1 under Telomir Pharmaceuticals. This move eliminates geographic fragmentation and provides unified control over the development and potential commercialization of Telomir-1 worldwide.

APR 24·Investing.com UK

Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition By Investing.com

Telomir Pharmaceuticals announced the completion of its acquisition of TELI Pharmaceuticals, consolidating global rights to its lead drug candidate, Telomir-1. This transaction involved issuing restricted shares to former TELI shareholders and a $1 million contribution from Bayshore Trust, with a potential for an additional $4 million investment based on milestones. The acquisition aims to eliminate geographic fragmentation of the Telomir-1 platform and accelerate its development for conditions like triple-negative breast cancer.

News on $TELO